Skip to results

Keyword or reference number

Keyword or reference number

Last updated date

Last updated date

Area of interest

Area of interest

Type (1 selected)

Type

Guidance programme (1 selected)

Guidance programme

Showing 1 to 25 of 799

Published guidance, NICE advice and quality standards
TitleReference numberPublishedLast updated
Tebentafusp for treating advanced uveal melanomaTA1027
Tirzepatide for managing overweight and obesityTA1026
Ublituximab for treating relapsing multiple sclerosisTA1025
Elranatamab for treating relapsed and refractory multiple myeloma after 3 or more treatmentsTA1023
Toripalimab with chemotherapy for untreated advanced oesophageal squamous cell cancer (terminated appraisal)TA1024
Crizotinib for treating ROS1-positive advanced non-small-cell lung cancerTA1021
Bevacizumab gamma for treating wet age-related macular degenerationTA1022
Eplontersen for treating hereditary transthyretin-related amyloidosisTA1020
Pembrolizumab with chemotherapy before surgery (neoadjuvant) then alone after surgery (adjuvant) for treating resectable non-small-cell lung cancerTA1017
Fedratinib for treating disease-related splenomegaly or symptoms in myelofibrosisTA1018
Crovalimab for treating paroxysmal nocturnal haemoglobinuria in people 12 years and overTA1019
Elafibranor for previously treated primary biliary cholangitisTA1016
Alectinib for adjuvant treatment of ALK-positive non-small-cell lung cancerTA1014
Teclistamab for treating relapsed and refractory multiple myeloma after 3 or more treatmentsTA1015
Avapritinib for treating advanced systemic mastocytosisTA1012
Danicopan with ravulizumab or eculizumab for treating paroxysmal nocturnal haemoglobinuriaTA1010
Quizartinib for induction, consolidation and maintenance treatment of newly diagnosed FLT3-ITD-positive acute myeloid leukaemiaTA1013
Belzutifan for treating tumours associated with von Hippel-Lindau diseaseTA1011
Latanoprost–netarsudil for previously treated primary open-angle glaucoma or ocular hypertensionTA1009
Trifluridine–tipiracil with bevacizumab for treating metastatic colorectal cancer after 2 systemic treatmentsTA1008
Rucaparib for maintenance treatment of relapsed platinum-sensitive ovarian, fallopian tube or peritoneal cancerTA1007
Empagliflozin for treating type 2 diabetes in people 10 to 17 years (terminated appraisal)TA1006
Evinacumab for treating homozygous familial hypercholesterolaemia in people 12 years and overTA1002
Exagamglogene autotemcel for treating transfusion-dependent beta-thalassaemia in people 12 years and overTA1003
Faricimab for treating visual impairment caused by macular oedema after retinal vein occlusionTA1004

Results per page

  1. 10
  2. 25
  3. 50
  4. All